Cardiomyocytes derived from pluripotent mammalian stem cells
The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC).
1. A method to generate adult-like cardiomyocytes from fetal-like cardiomyocytes, comprising the steps of:
(a) providing one or more fetal-like cardiomyocyte(s) differentiated from stem cells;
(b) contacting said one or more fetal-like cardiomyocytes with a culture medium composition so as to allow maturation of said one or more fetal-like cardiomyocytes into adult-like cardiomyocytes, wherein the culture medium composition comprises:
a lipid mixture comprising at least cholesterol, linoleic acid, oleic acid and at least one selected from the group consisting of linolenic acid, palmitic acid, arachidonic acid, myristic acid, palmitoleic acid, and stearic acid;
a taurine compound; and
a creatine compound.
2. The method of claim 1 , wherein the lipid mixture comprises, linolenic acid and palmitic acid.
3. The method of claim 1 , wherein the lipid mixture comprises cholesterol, linolenic acid, linoleic acid, palmitic acid, arachidonic acid, myristic acid, oleic acid, palmitoleic acid and stearic acid.
4. The method of claim 1 , wherein the lipid mixture comprises about 0.01 μg/ml to about 5 μg/ml of cholesterol.
5. The method of claim 1 , wherein the lipid mixture comprises about 0.01 μg/mL to about 20 μg/mL of linoleic acid.
6. The method of claim 1 , wherein the lipid mixture comprises about 0.01 μg/mL to about 20 μg/mL of palmitic acid.
7. The method of claim 1 , wherein the lipid mixture comprises about 0.01 μg/mL to about 20 μg/mL linolenic acid.
8. The method of claim 1 , wherein the culture medium composition further comprises a carnitine compound.
9. The method of claim 8 , wherein the culture medium composition comprises about 0.5 mM to about 3.5 mM of carnitine.
10. The method of claim 8 , wherein the culture medium composition comprises about 1.5 mM to about 2.25 mM of carnitine.
11. The method of claim 1 , wherein the culture medium composition comprises about 2 mM to about 7 mM of taurine.
12. The method of claim 1 , wherein the culture medium composition comprises about 1 mM to about 10 mM of creatine.
13. The method of claim 1 , wherein the culture medium composition further comprises insulin, transferrin and selenium.
14. The method of claim 13 , wherein the culture medium composition comprises about 5 mg/L to about 15 mg/L of insulin, about 3 mg/L to about 8 mg/L of transferrin, and about 0.005 mg/L to about 0.0075 mg/L of selenium.
15. The method of claim 1 , wherein the culture medium composition further comprises about 0.01 mg/ml to about 10 mg/ml of polyvinyl alcohol (PVA).
16. The method of claim 1 , wherein the culture medium composition is serum-free.
17. The method of claim 1 , wherein the culture medium composition further comprises a thyroid hormone-like compound.
18. The method of claim 17 , wherein the thyroid hormone-like compound is triiodothyronine (T3).
19. The method according to claim 1 , wherein the stem cells comprise pluripotent stem cells, wherein the pluripotent stem cells comprise human embryonic stem cells.
20. The method according to claim 1 , wherein the stem cells comprise pluripotent stem cells and wherein the pluripotent stem cells comprise human induced pluripotent stem cells.
21. The method of claim 1 , wherein the one or more fetal-like cardiomyocytes are in contact with the culture medium for a period of 2 weeks, 3 weeks, 6 weeks, or up to 6 months.
22. The method according to claim 1 , wherein the culture medium composition comprises polyvinylalcohol.
23. The method according to claim 1 , wherein the culture medium composition comprises polyvinylalcohol and T3.
24. A method to generate adult-like cardiomyocytes from fetal-like cardiomyocytes, comprising the steps of:
(a) providing one or more fetal-like cardiomyocyte(s) differentiated from stem cells;
(b) contacting said one or more fetal-like cardiomyocytes with a culture medium composition so as to allow maturation of said one or more fetal-like cardiomyocytes into adult-like cardiomyocytes, wherein the culture medium composition comprises:
a lipid mixture at least comprising cholesterol and the fatty acids linolenic acid, linoleic acid and palmitic acid;
a taurine compound; and
a creatine compound.
25. The method of claim 24 , wherein the lipid mixture comprises about 0.01 mg/ml to about 5 μg/ml of cholesterol.
26. The method of claim 24 , wherein the culture medium composition further comprises a carnitine compound.
27. The method of claim 24 , wherein the culture medium composition is serum-free.
28. The method of claim 24 , wherein the culture medium composition further comprises triiodothyronine (T3).
29. A method to generate adult-like cardiomyocytes from fetal-like cardiomyocytes, comprising the steps of:
(a) providing one or more fetal-like cardiomyocyte(s) differentiated from stem cells;
(b) contacting said one or more fetal-like cardiomyocytes with a culture medium composition so as to allow maturation of said one or more fetal-like cardiomyocytes into adult-like cardiomyocytes, wherein the culture medium composition comprises:
a lipid mixture at least comprising cholesterol;
a taurine compound; and
a creatine compound.
30. The method of claim 29 , wherein the lipid mixture comprises cholesterol, linolenic acid, linoleic acid, palmitic acid, arachidonic acid, myristic acid, oleic acid, palmitoleic acid and stearic acid.
31. The method of claim 29 , wherein the lipid mixture comprises about 0.01 μg/ml to about 5 μg/ml of cholesterol.
32. The method of claim 29 , wherein the culture medium composition further comprises a carnitine compound.
33. The method of claim 29 , wherein the culture medium composition further comprises triiodothyronine (T3).
34. A method to generate adult-like cardiomyocytes from fetal-like cardiomyocytes, comprising the steps of:
(a) providing one or more fetal-like cardiomyocyte(s) differentiated from stem cells;
(b) contacting said one or more fetal-like cardiomyocytes with a culture medium composition so as to allow maturation of said one or more fetal-like cardiomyocytes into adult-like cardiomyocytes, wherein the culture medium composition comprises:
a lipid mixture;
a taurine compound;
a creatine compound; and
polyvinylalcohol and/or T3.
35. The method of claim 34 , wherein the lipid mixture comprises cholesterol, linolenic acid, linoleic acid, palmitic acid, arachidonic acid, myristic acid, oleic acid, palmitoleic acid and stearic acid.
36. The method of claim 34 , wherein the lipid mixture comprises about 0.01 μg/ml to about 5 μg/ml of cholesterol.
37. The method of claim 34 , wherein the culture medium composition further comprises a carnitine compound.
38. The method of claim 34 , wherein the one or more fetal-like cardiomyocytes are in contact with the culture medium for a period of 2 weeks, 3 weeks, 6 weeks, or up to 6 months.
39. A method to generate adult-like cardiomyocytes from fetal-like cardiomyocytes, comprising the steps of:
(a) providing one or more fetal-like cardiomyocyte(s) differentiated from stem cells;
(b) contacting said one or more fetal-like cardiomyocytes with a culture medium composition so as to allow maturation of said one or more fetal-like cardiomyocytes into adult-like cardiomyocytes, wherein the culture medium composition comprises:
a lipid mixture;
a taurine compound;
a creatine compound; and
polyvinylalcohol and/or T3,
wherein the lipid mixture at least comprises cholesterol and the fatty acids linolenic acid, linoleic acid and palmitic acid.
40. The method of claim 39 , wherein the lipid mixture comprises about 0.01 μg/ml to about 5 μg/ml of cholesterol.
41. The method of claim 39 , wherein the culture medium composition further comprises a carnitine compound.
42. The method of claim 39 , wherein the culture medium composition is serum-free.
43. The method of claim 39 , wherein the one or more fetal-like cardiomyocytes are in contact with the culture medium for a period of 2 weeks, 3 weeks, 6 weeks, or up to 6 months.